Formulation And Evaluation Of Rapidly Disintegrating Oral Ultrathin Film Of Lamotrigine For Treatment Of Childhood Epilepsy

Abstract

The advancement of Rapidly Disintegrating Oral Ultrathin Films (RDOFs) represents a novel and promising approach to conventional oral drug delivery systems. These films present a user-friendly, self-administerable platform that dissolves swiftly in the oral cavity, facilitating rapid drug absorption through the pre-gastric route and potentially leading to a quicker onset of therapeutic action. Their distinct advantages—including ease of administration and enhanced patient compliance—have made RDOFs increasingly attractive for both systemic and localized drug delivery. This research focuses on the design and evaluation of Lamotrigine-loaded RDOFs, targeting the treatment of pediatric epilepsy. Conventional oral formulations often pose challenges for children due to swallowing difficulties, necessitating the development of more acceptable and patient-centric dosage forms. The objective of this formulation was to enhance the drug’s bioavailability and ensure better adherence to therapy. The development process incorporated the selection of suitable film-forming polymers, evaluation of the films' mechanical characteristics, and execution of in vitro disintegration and drug release assessments. The findings demonstrate that Lamotrigine-based RDOFs hold significant potential as an efficient and practical alternative for managing epilepsy in pediatric populations, offering improved bioavailability, simplified administration, and greater treatment compliance.